Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 5/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 4/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556846 | 1.00 | CISD1 (0.51) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL7556852 | 0.82 | CSNK2A2 (0.39) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1249065 | 0.72 | PIM1 (0.60) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1249070 | 0.72 | PIM1 (0.60) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL14262550 | 0.70 | GSK3B (0.69) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1247700 | 0.69 | CISD1 (0.75) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1247698 | 0.69 | CISD1 (0.75) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1125013 | 0.69 | PIM1 (0.72) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL2555241 | 0.69 | PIM1 (0.72) | CISD1MAOAMAOBGSK3BPIM1 | |
| SCHEMBL1125015 | 0.69 | PIM1 (0.72) | CISD1MAOAMAOBGSK3BPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | CISD1 3846/4885MAOA 3434/4885MAOB 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.